17 results

• After Recalling Oxbryta, Pfizer Seeks Dismissal of Class Action Brought by Former Users

  March 7, 2025

  Irvin Jackson

  Pfizer attorneys are seeking to have an Oxbryta class action lawsuit dismissed before they have to face plaintiffs before juries.

• Oxbryta Injury Lawsuit Over Discontinued Sickle Cell Disease Drug Set for Trial in June 2027

  February 28, 2025

  Irvin Jackson

  A federal judge has scheduled an Oxbryta lawsuit to go before a jury on June 7, 2027, which may be the first trial over side effects of the discontinued sickle cell disease drug.

• Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024

  December 30, 2024

  Irvin Jackson

  Former users of the recalled sickle cell disease drug Oxbryta have filed a class action lawsuit, claiming the manufacturer failed to warn consumers about risks associated with the medication, which can result in stroke and death.

• Lawsuit Alleges Oxbryta Side Effects Resulted in Higher Rate of Vaso-Occlusive Crisis, Other Debilitating Symptoms

  November 19, 2024

  Irvin Jackson

  Illinois man has filed an Oxbryta lawsuit, indicating that the recalled sickle cell disease treatment caused a stroke shortly before Pfizer pulled the drug from the market.

• Oxbryta Recall Lawsuits Claim Drug Manufacturer Knew About Fatality Risks for Years

  November 8, 2024

  Russell Maas

  Although hundreds of Oxbryta fatalities were reported through the FDA's adverse event reporting system, lawsuits point out that it took Pfiizer years to issue an Oxbryta recall.

• Oxbryta Lawsuit Filed Over Vaso-Occlusive Crisis (VOC) from Recalled Sickle Cell Disease Drug

  October 28, 2024

  Irvin Jackson

  Illinois man indicates he suffered a stroke, vision loss and hospitalization due to the side effects of Oxbryta, which is a sickle cell disease medication recalled last month.

• Oxbryta Recall Announced After Studies Show Sickle Cell Drug’s Risks Outweigh Benefits

  September 26, 2024

  Martha Garcia

  Pfizer announces worldwide recall for the sickle cell anemia drug Oxbryta, after reports of eight patient deaths and a safety review by European regulators.